Skip to main content

Amgen

Amgen Inc. is an American biopharmaceutical enterprise that discovers, develops, manufactures, and delivers innovative human therapeutics for serious illnesses. The company focuses its operational activities across four core therapeutic areas: oncology and hematology, cardiovascular disease, general medicine, and rare inflammatory diseases. Its commercial product portfolio comprises widely used biologic medicines such as Enbrel for rheumatoid arthritis, Prolia and Xgeva for bone health, Repatha for cholesterol management, Otezla, and Tepezza. Principal revenue drivers consist of worldwide commercial sales of proprietary prescription biopharmaceuticals, alongside royalty income, technology licensing agreements, and corporate research collaborations. Amgen serves diverse end markets encompassing hospital networks, retail and specialty pharmacies, medical practitioners, and patients across health authority systems in North America, Europe, Asia-Pacific, and Latin America. The enterprise maintains a leading global position as one of the world's largest independent biotechnology companies by total annual revenue and market capitalization. Headquartered in Thousand Oaks, California, the company's common stock is listed on the Nasdaq Global Select Market under the ticker symbol AMGN.

117 of the funds FundTelligence covers report a position in Amgen.

Legal name
Amgen Inc.
Sector
Health Care
Country
United States
Funds holding it
117
Exposure themes
Multiple, Treatment, Women's Health

Funds holding Amgen

Showing the 8 largest of 117 funds holding it.

Loading...